Janux Therapeutics JANX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Janux Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Janux Therapeutics's operating income?
- Janux Therapeutics (JANX) reported operating income of -$34.21M in Q1 2026.
- How has Janux Therapeutics's operating income changed year-over-year?
- Janux Therapeutics's operating income increased by 2.0% year-over-year, from -$34.9M to -$34.21M.
- What is the long-term trend for Janux Therapeutics's operating income?
- Over 4 years (2021 to 2025), Janux Therapeutics's operating income has grown at a 47.9% compound annual growth rate (CAGR), from -$32.93M to -$157.67M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.